Xoma sits on a great library that has so much potential. However they need to do more partnerships to exploit their assets more. To me Xoma could be a $20 per share stock again. They just need to get it going a bit by pushing forward with big pharma and open their assets to new developments together. In other words licensing agreements. All JMHO.